Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Aichi Cancer Center Hospital, Nagoya

Nagoya University Hospital, Nagoya

Fujita Health University Hospital, Toyoake

National Cancer Center Hospital East, Kashiwa

National Hospital Organization Shikoku Cancer Center, Matsuyama

Kurume University Hospital, Kurume

Hokkaido Cancer Center, Sapporo

Hyogo Cancer Center, Akashi

Kobe City Medical Center General Hospital, Kobe

Kanazawa University Hospital, Kanazawa

Iwate Medical University Hospital, Morioka

Kanagawa Cancer Center, Yokohama

Matsuzaka Citizen's Hospital, Matsuzaka

Sendai Kousei Hospital, Sendai

Kurashiki Central Hospital, Kurashiki

Kansai Medical University Hospital, Hirakata

Kindai University Hospital, Sayama

Saitama Cancer Center, Shinden

Shizuoka Cancer Center, Nagaizumi-cho

Jichi Medical University Hospital, Shimotsuke

Juntendo University Hospital, Bunkyo-ku

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku

National Cancer Center Hospital, Chuo-ku

Cancer Institute Hospital, Koto-ku

Chiba University Hospital, Chiba

Kyushu University Hospital, Fukuoka

National Hospital Organization Kyushu Cancer Center, Fukuoka

Kyoto University Hospital, Kyoto

Niigata Cancer Center Hospital, Niigata

Okayama University Hospital, Okayama

Osaka City General Hospital, Osaka

Osaka International Cancer Institute, Osaka

Wakayama Medical University Hospital, Wakayama